Commercialization Reports. On a semi-annual basis after Marketing Approval of any Licensed Product, Janssen shall provide to the JSC a high-level summary report of its Commercialization launch status, activities, and performance with respect to each Licensed Product since the previous JSC summary. At each JSC meeting, Janssen shall provide additional information as reasonably requested by Fate’s JSC representatives with respect to the Commercialization activities summarized in such report or otherwise conducted or anticipated to be conducted for each Licensed Product.

Commercialization Reports. Each Party shall keep the China Committee fully informed regarding the progress and results of Commercialization activities for Products in the Territory, including an annual review of results versus plans (as set forth in the Commercialization Plan(s)).

Commercialization Reports. Beginning ​ (​) calendar quarters prior to the anticipated First Commercial Sale of a Licensed Product in the Field in the Territory, and every calendar quarter thereafter, Licensee shall report to Bioeq # the Commercialization activities (or preparations for First Commercial Sale, as applicable) performed in relation to the Licensed Products in the preceding four (4) calendar quarters, # the planned Commercialization activities (or preparations for First Commercial Sale, as applicable) in relation to the Licensed Products planned for the four (4) calendar quarters following such quarter, and # any significant changes in the market or of the competitive landscape. In addition, Licensee shall promptly respond to Bioeq’s reasonable questions or requests for information relating to Licensee’s and its Affiliates’ Commercialization activities with respect to the Licensed Products in the Field in the Territory, including activities performed to prepare for the First Commercial Sale.

Commercialization Reports. Abbott shall keep the JSC regularly informed of the progress of its efforts to Commercialize Products in the Field and in the Territory. Without limiting the generality of the foregoing, Abbott shall provide Enanta with semi-annual written updates to each Marketing and Sales Plan, which shall # summarize Abbott’s efforts to Commercialize Products, # identify the Regulatory Filings and Drug Approval Applications with respect to Candidates that Abbott or any of its Affiliates or Sublicensees have filed in the prior twelve (12) month period or reasonably expect to make in the following twelve (12) month period, # identify the Regulatory Approvals with respect to Products that Abbott or any of its Affiliates or Sublicensees have obtained in the prior twelve (12) month period or reasonably expect to obtain in the following twelve (12) month period, and # summarize all clinical and other data generated by Abbott with respect to Products. In addition, Abbott shall provide such additional information that it has in its possession as may be reasonably requested from time to time by the JSC regarding the Commercialization of any Product.

Commercialization Reports. Without limiting [Section 3.4.2] (Commercialization Records), within ​ following the end of each Calendar Year during which Licensee is conducting Commercialization activities hereunder, Licensee shall provide [[AstraZeneca:Organization]] with written reports of the Commercialization activities it has performed, or caused to be performed, in respect of Licensed Product since the preceding report (or, with respect to the first such report, since the Effective Date), and the future Commercialization activities it expects to initiate in respect of Licensed Product during the following twelve (12)-month period. Each such report shall be ​ with its obligations set forth in [Section 3.4.1] (Diligence). Notwithstanding the foregoing, if [[AstraZeneca:Organization]] or any of its Affiliates ​, Licensee, acting reasonably, shall be entitled to omit those certain details it reasonably deems to be competitively sensitive information from its reports under this [Section 3.4.3] in respect of such Licensed Product.

Commercialization Reports. Zai shall update the JSC at each regularly scheduled JSC meeting regarding Zai’s Commercialization activities with respect to the Products in the Territory. Each such update shall be in a form to be agreed by the JSC and shall summarize Zai’s, its Affiliates’ and Sublicensees’ significant Commercialization activities with respect to the Products in the Territory, covering subject matter at a level of detail reasonably required by TPTX and sufficient to enable TPTX to determine Zai’s compliance with its diligence obligations pursuant to Section 8.1. In addition, Zai shall make available to TPTX such additional information about its Commercialization activities as may be reasonably requested by TPTX from time to time. All updates and reports generated pursuant to this Section 8.3 shall be the Confidential Information of Zai.

Commercialization Reports. Ji Xing shall keep [[Cytokinetics:Organization]] informed of its, its Affiliates’ and sublicensees’ Commercialization activities with respect to the Product. Without limiting the foregoing, Ji Xing shall update the JCC at each regularly scheduled JCC meeting regarding the Commercialization activities with respect to the Product in the Territory. Each such update shall be in a form to be agreed by the JCC and shall summarize Ji Xing’s, its Affiliates’ and sublicensees’ significant Commercialization activities with respect to the Product in the Territory, covering subject matter at a level of detail reasonably required by [[Cytokinetics:Organization]] and sufficient to enable [[Cytokinetics:Organization]] to determine Ji Xing’s compliance with its diligence obligations pursuant to Section 8.2. In addition, Ji Xing shall make available to [[Cytokinetics:Organization]] such additional information about its Commercialization activities as may be reasonably requested by [[Cytokinetics:Organization]] from time to time. Ji Xing shall ​.

Commercialization Reports. Acadia shall provide to Stoke an annual report on its Commercialization of the Licensed Products in the Territory. Each such report shall summarize Acadia’s and its Affiliates’ and sublicensees’ significant Commercialization activities with respect to the Licensed Products throughout the Territory and will be at a level of detail sufficient to enable Stoke to determine Acadia’s compliance with its diligence obligations in [Section 5.5(b)]. Without limiting the foregoing, Acadia shall timely respond to Stoke’s representatives’ reasonable questions or requests for additional information relating to such Commercialization activities.

Commercialization Reports. At each JCC meeting, # Stoke shall provide the JCC a summary of the progress and results of Commercialization activities for any [[Unknown Identifier]] Co-Co Product for which Stoke is the Lead Commercialization Party or otherwise responsible for, # Acadia shall provide the JCC a summary of the progress and results of Commercialization activities for any [[Unknown Identifier]] Co-Co Product for which Acadia is the Lead Commercialization [[Person A:Person]] Party or otherwise responsible for. Without limiting the foregoing, at each meeting of the JCC, each Party shall provide to the JCC a summary of sales forecasts, sales performance reports, and other information for such [[Unknown Identifier]] Co-Co Product, as applicable.

Commercialization Reports. Ji Xing shall keep [[Cytokinetics:Organization]] informed of its, its Affiliates’ and sublicensees’ Commercialization activities with respect to the Product. Without limiting the foregoing, Ji Xing shall update the JCC at each regularly scheduled JCC meeting regarding the Commercialization activities with respect to the Product in the Territory. Each such update shall be in a form to be agreed by the JCC and shall summarize Ji Xing’s, its Affiliates’ and sublicensees’ significant Commercialization activities with respect to the Product in the Territory, covering subject matter at a level of detail reasonably required by [[Cytokinetics:Organization]] and sufficient to enable [[Cytokinetics:Organization]] to determine Ji Xing’s compliance with its diligence obligations pursuant to Section 8.2. In addition, Ji Xing shall make available to [[Cytokinetics:Organization]] such additional information about its Commercialization activities as may be reasonably requested by [[Cytokinetics:Organization]] from time to time. Ji Xing shall ​.